Stocks Health care PCSA
NASDAQ · Health careProcessa Pharmaceuticals, Inc. (PCSA)
It posted a net loss of $13.4M. At June 30, 2026 it held $196.3K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Processa Pharmaceuticals, Inc.
- Net worth
- Processa Pharmaceuticals, Inc. has a market value (market cap) of $5.1M at the latest share price, and shareholders' equity of -$317.3K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $0, with a net loss of $27.4M.
- Cash flow
- In fiscal 2025 operations used $11.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Processa Pharmaceuticals, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Processa Pharmaceuticals, Inc. does
Processa Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PCSA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$13.6M | -$10.36 | n/a |
| 2024 | n/a | -$11.9M | -$96.78 | -$11.2M |
| 2023 | n/a | -$11.1M | -$212.07 | -$8.1M |
| 2022 | $0 | -$27.4M | -$851.51 | n/a |
| 2021 | $0 | -$11.4M | -$18.76 | n/a |
| 2020 | n/a | -$14.4M | -$63.52 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Dividends
It paid out $42.9K in cash dividends.
| Fiscal year | Per share | Paid out | Of profit |
|---|---|---|---|
| 2015 | n/a | $42.9K | n/a |
| 2014 | n/a | $45.6K | n/a |
Latest SEC filings
What Processa Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Other event 8-K/A
- August 18, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026
- August 4, 2026
- July 29, 2026
- June 18, 2026Proxy statement DEF 14A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026
- April 30, 2026
- April 30, 2026
Insider trades
What the people running Processa Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 8, 2026 | Ng George KChief Executive Officer, Director | Exercised options | 1,600 | - |
| July 1, 2026 | Ng George KChief Executive Officer, Director | Bought | 3,057 | $5.9K |
| June 30, 2026 | Young DavidPres. Research & Development, Director | Bought | 2,531 | $4.9K |
| June 30, 2026 | Skibsted RussellChief Financial Officer | Bought | 3,277 | $6.3K |
| June 30, 2026 | Lin PatrickChief Business - Strategy Off | Bought | 2,106 | $4.1K |
| June 30, 2026 | Guy WendyChief Administrative Officer | Bought | 2,436 | $4.7K |
| June 26, 2026 | Baluch KhosoDirector | Exercised options | 203 | - |
| June 26, 2026 | Neal James RDirector | Exercised options | 203 | - |
Who owns PCSA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| HX Entertainment Ltd13D, may seek influence | 13% | February 23, 2026 |
| Mitchell P. Kopin13G, passive with 2 related filers | 8.1% | February 13, 2026 |
| CVI Investments, Inc.13G, passive with 1 related filers | 7% | May 15, 2026 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 5.8% | August 18, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 96,791 shares in total, about $177.1K at the last price.
| Holder | Shares |
|---|---|
| Young DavidPres. Research & Development, Director | 21,729 |
| Ng George KChief Executive Officer, Director | 17,092 |
| Skibsted RussellChief Financial Officer | 16,689 |
| Guy WendyChief Administrative Officer | 14,394 |
| Lin PatrickChief Business - Strategy Off | 13,113 |
| Bigora SianChief Development Officer | 7,481 |
| Baluch KhosoDirector | 2,528 |
| Pannu GeraldineDirector | 2,391 |
| Neal James RDirector | 1,021 |
| Yorke Justin WDirector | 353 |
Questions about PCSA
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as PCSA. Its shares trade on NASDAQ under the ticker PCSA.
What is Processa Pharmaceuticals, Inc.'s net worth?
Processa Pharmaceuticals, Inc. has a market value (market cap) of $5.1M at the latest share price, and shareholders' equity of -$317.3K on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Processa Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $13.4M.
When did Processa Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 5, 2026.
When is Processa Pharmaceuticals, Inc.'s next earnings report?
Processa Pharmaceuticals, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare PCSA with
Follow PCSA
Get an email when Processa Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Processa Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.